Literature DB >> 12203141

Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia.

M van Agthoven1, M T Groot, L F Verdonck, B Löwenberg, A V M B Schattenberg, M Oudshoorn, A Hagenbeek, J J Cornelissen, C A Uyl-de Groot, R Willemze.   

Abstract

Allogeneic stem cell transplantation (SCT) is one of the most expensive medical procedures. However, only a few studies to date have addressed the costs of HLA-identical sibling transplantation and only one study has reported costs of unrelated transplantation. No recent cost analysis with a proper follow-up period and donor identification expenses is available on related or voluntary matched unrelated donor (MUD) SCT for adult AML or ALL. Therefore, we calculated direct medical (hospital) costs based on 97 adults who underwent HLA-identical sibling bone marrow transplantation (BMT) or peripheral blood stem cell transplantation (PBSCT), and patients who received a graft from a MUD between 1994 and 1999. The average costs per transplanted patient were Euro 98,334 (BMT), Euro 151,754 (MUD), and Euro 98,977 (PBSCT), including donor identification expenses, 2 years follow-up and costs of patients who were not transplanted after they had been planned to receive an allograft. The majority of these costs was generated during the hospitalisation for graft infusion. For MUD transplants, nearly one-third of these costs was spent on the search for a suitable donor. For patients who were alive after 2 years, cumulative expenses were calculated to be Euro 103,509 (BMT), Euro 173,587 (MUD), and Euro 105,906 (PBSCT).

Entities:  

Mesh:

Year:  2002        PMID: 12203141     DOI: 10.1038/sj.bmt.1703641

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  16 in total

1.  Association of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia: An Analysis From the Acute Leukemia Working Party of the EBMT.

Authors:  Sebastian Giebel; Myriam Labopin; Adalberto Ibatici; Paul Browne; Tomasz Czerw; Gerard Socie; Ali Unal; Slawomira Kyrcz-Krzemien; Andrea Bacigalupo; Hakan Goker; Mike Potter; Caroline L Furness; Grant McQuaker; Dietrich Beelen; Noel Milpied; Antonio Campos; Charles Craddock; Arnon Nagler; Mohamad Mohty
Journal:  Oncologist       Date:  2016-02-11

2.  Costs of allogeneic hematopoietic cell transplantation with high-dose regimens.

Authors:  Akiko M Saito; Corey Cutler; David Zahrieh; Robert J Soiffer; Vincent T Ho; Edwin P Alyea; John Koreth; Joseph H Antin; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2008-02       Impact factor: 5.742

3.  Cost-effectiveness and clinical outcomes of double versus single cord blood transplantation in adults with acute leukemia in France.

Authors:  Myriam Labopin; Annalisa Ruggeri; Norbert Claude Gorin; Eliane Gluckman; Didier Blaise; Lionel Mannone; Noel Milpied; Ibrahim Yakoub-Agha; Eric Deconinck; Mauricette Michallet; Nathalie Fegueux; Gerard Socié; Stephanie Nguyen; Jean Yves Cahn; Thierry de Revel; Federico Garnier; Catherine Faucher; Namik Taright; Chantal Kenzey; Fernanda Volt; Dominique Bertrand; Mohamad Mohty; Vanderson Rocha
Journal:  Haematologica       Date:  2013-10-18       Impact factor: 9.941

4.  Hospital length of stay in the first 100 days after allogeneic hematopoietic cell transplantation for acute leukemia in remission: comparison among alternative graft sources.

Authors:  Karen K Ballen; Steven Joffe; Ruta Brazauskas; Zhiwei Wang; Mahmoud D Aljurf; Görgün Akpek; Christopher Dandoy; Haydar A Frangoul; César O Freytes; Nandita Khera; Hillard M Lazarus; Charles F LeMaistre; Paulette Mehta; Susan K Parsons; David Szwajcer; Celalettin Ustun; William A Wood; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-23       Impact factor: 5.742

5.  Clinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients.

Authors:  Lynn El Haddad; Shashank S Ghantoji; Anne K Park; Marjorie V Batista; Jonathan Schelfhout; Jack Hachem; Yadira Lobo; Ying Jiang; Gabriela Rondon; Richard Champlin; Roy F Chemaly
Journal:  J Med Virol       Date:  2019-09-03       Impact factor: 2.327

Review 6.  Costs and cost-effectiveness of hematopoietic cell transplantation.

Authors:  Jaime M Preussler; Ellen M Denzen; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2012-04-03       Impact factor: 5.742

Review 7.  Halfway there: the past, present and future of haploidentical transplantation.

Authors:  M Slade; B Fakhri; B N Savani; R Romee
Journal:  Bone Marrow Transplant       Date:  2016-07-25       Impact factor: 5.483

8.  Costs of pediatric allogeneic hematopoietic-cell transplantation.

Authors:  Navneet S Majhail; Jaya M Mothukuri; Margaret L Macmillan; Michael R Verneris; Paul J Orchard; John E Wagner; Daniel J Weisdorf
Journal:  Pediatr Blood Cancer       Date:  2010-01       Impact factor: 3.167

Review 9.  Transplantation of haploidentically mismatched stem cells for the treatment of malignant diseases.

Authors:  Franco Aversa; Massimo F Martelli
Journal:  Springer Semin Immunopathol       Date:  2004-09-11

10.  Is a matched unrelated donor search needed for all allogeneic transplant candidates?

Authors:  Stefan O Ciurea; Maria Cecilia Borges Bittencourt; Denái R Milton; Kai Cao; Piyanuch Kongtim; Gabriela Rondon; Julianne Chen; Marina Konopleva; Jorge M Ramos Perez; Mohammed F El Shazly; Majdi Aljadayeh; Michele Alvarez; Jin Im; Gheath Al-Atrash; Rohtesh Mehta; Uday Popat; Qaiser Bashir; Betul Oran; Chitra M Hosing; Issa F Khouri; Partow Kebriaei; Richard E Champlin
Journal:  Blood Adv       Date:  2018-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.